279 related articles for article (PubMed ID: 18379730)
1. Clinical trials and biomarker development with molecularly targeted agents and radiotherapy.
Dhani N; Siu LL
Cancer Metastasis Rev; 2008 Sep; 27(3):339-49. PubMed ID: 18379730
[TBL] [Abstract][Full Text] [Related]
2. New science-based endpoints to accelerate oncology drug development.
Kelloff GJ; Sigman CC
Eur J Cancer; 2005 Mar; 41(4):491-501. PubMed ID: 15737552
[TBL] [Abstract][Full Text] [Related]
3. Molecularly targeted therapies for malignant gliomas: advances and challenges.
Penas-Prado M; Gilbert MR
Expert Rev Anticancer Ther; 2007 May; 7(5):641-61. PubMed ID: 17492929
[TBL] [Abstract][Full Text] [Related]
4. Clinical biomarkers of kinase activity: examples from EGFR inhibition trials.
Krause M; Baumann M
Cancer Metastasis Rev; 2008 Sep; 27(3):387-402. PubMed ID: 18427731
[TBL] [Abstract][Full Text] [Related]
5. Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice.
Kinders R; Parchment RE; Ji J; Kummar S; Murgo AJ; Gutierrez M; Collins J; Rubinstein L; Pickeral O; Steinberg SM; Yang S; Hollingshead M; Chen A; Helman L; Wiltrout R; Simpson M; Tomaszewski JE; Doroshow JH
Mol Interv; 2007 Dec; 7(6):325-34. PubMed ID: 18199854
[TBL] [Abstract][Full Text] [Related]
6. Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers.
Lee JW; Figeys D; Vasilescu J
Adv Cancer Res; 2007; 96():269-98. PubMed ID: 17161683
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamic biomarkers for molecular cancer therapeutics.
Sarker D; Workman P
Adv Cancer Res; 2007; 96():213-68. PubMed ID: 17161682
[TBL] [Abstract][Full Text] [Related]
8. Use of molecular biomarkers for predicting the response to radiotherapy with or without chemotherapy.
Riesterer O; Milas L; Ang KK
J Clin Oncol; 2007 Sep; 25(26):4075-83. PubMed ID: 17827456
[TBL] [Abstract][Full Text] [Related]
9. Biomarkers for DNA DSB inhibitors and radiotherapy clinical trials.
Liu SK; Olive PL; Bristow RG
Cancer Metastasis Rev; 2008 Sep; 27(3):445-58. PubMed ID: 18516501
[TBL] [Abstract][Full Text] [Related]
10. From darkness to light with biomarkers in early clinical trials of cancer drugs.
Carden CP; Banerji U; Kaye SB; Workman P; de Bono JS
Clin Pharmacol Ther; 2009 Feb; 85(2):131-3. PubMed ID: 19151637
[TBL] [Abstract][Full Text] [Related]
11. Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents.
Le Tourneau C; Vidal L; Siu LL
Drug Resist Updat; 2008 Jun; 11(3):99-109. PubMed ID: 18515176
[TBL] [Abstract][Full Text] [Related]
12. Phase 0 clinical trials in oncology: a paradigm shift for early drug development?
Takimoto CH
Cancer Chemother Pharmacol; 2009 Mar; 63(4):703-9. PubMed ID: 18615251
[TBL] [Abstract][Full Text] [Related]
13. [Possibilities and limitations of stratified medicine based on biomarkers and targeted therapies in oncology].
Ludwig WD
Z Evid Fortbild Qual Gesundhwes; 2012; 106(1):11-22. PubMed ID: 22325103
[TBL] [Abstract][Full Text] [Related]
14. Biomarkers of clinical trials using molecular inhibitors and radiotherapy: state-of-the-art. Preface.
Bristow RG
Cancer Metastasis Rev; 2008 Sep; 27(3):337-8. PubMed ID: 18427733
[No Abstract] [Full Text] [Related]
15. Is tailored therapy feasible in oncology?
Gasparini G; Longo R; Torino F; Gattuso D; Morabito A; Toffoli G
Crit Rev Oncol Hematol; 2006 Jan; 57(1):79-101. PubMed ID: 16337806
[TBL] [Abstract][Full Text] [Related]
16. End points in cancer clinical trials and the drug approval process.
Schilsky RL
Clin Cancer Res; 2002 Apr; 8(4):935-8. PubMed ID: 11948095
[TBL] [Abstract][Full Text] [Related]
17. Molecularly targeted oncology therapeutics and prolongation of the QT interval.
Strevel EL; Ing DJ; Siu LL
J Clin Oncol; 2007 Aug; 25(22):3362-71. PubMed ID: 17664484
[TBL] [Abstract][Full Text] [Related]
18. Parallel anticancer drug development and molecular stratification to qualify predictive biomarkers: dealing with obstacles hindering progress.
Garcia VM; Cassier PA; de Bono J
Cancer Discov; 2011 Aug; 1(3):207-12. PubMed ID: 22586572
[TBL] [Abstract][Full Text] [Related]
19. Exploitable mechanisms for combining drugs with radiation: concepts, achievements and future directions.
Bentzen SM; Harari PM; Bernier J
Nat Clin Pract Oncol; 2007 Mar; 4(3):172-80. PubMed ID: 17327857
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers in drug development: friend or foe? A personal reflection gained working within oncology.
Carroll KJ
Pharm Stat; 2007; 6(4):253-60. PubMed ID: 17351904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
